328 related articles for article (PubMed ID: 26826307)
41. Biodegradable particles as vaccine delivery systems: size matters.
Joshi VB; Geary SM; Salem AK
AAPS J; 2013 Jan; 15(1):85-94. PubMed ID: 23054976
[TBL] [Abstract][Full Text] [Related]
42. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response.
Liu X; Liu J; Liu D; Han Y; Xu H; Liu L; Leng X; Kong D
Biomater Sci; 2019 Dec; 7(12):5516-5527. PubMed ID: 31670734
[TBL] [Abstract][Full Text] [Related]
43. Characterization of protein-adjuvant coencapsulation in microparticles for vaccine delivery.
Mathew S; Lendlein A; Wischke C
Eur J Pharm Biopharm; 2014 Jul; 87(2):403-7. PubMed ID: 24747810
[TBL] [Abstract][Full Text] [Related]
44. Co-encapsulated CpG oligodeoxynucleotides and ovalbumin in PLGA microparticles; an in vitro and in vivo study.
San Román B; Gómez S; Irache JM; Espuelas S
J Pharm Pharm Sci; 2014; 17(4):541-53. PubMed ID: 25579433
[TBL] [Abstract][Full Text] [Related]
45. Mucosal application of cationic poly(D,L-lactide-co-glycolide) microparticles as carriers of DNA vaccine and adjuvants to protect chickens against infectious bursal disease.
Negash T; Liman M; Rautenschlein S
Vaccine; 2013 Aug; 31(36):3656-62. PubMed ID: 23777953
[TBL] [Abstract][Full Text] [Related]
46. In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A.
Guldner D; Hwang JK; Cardieri MC; Eren M; Ziaei P; Norton MG; Souza CD
PLoS One; 2016; 11(11):e0165477. PubMed ID: 27835636
[TBL] [Abstract][Full Text] [Related]
47. Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine.
Bershteyn A; Hanson MC; Crespo MP; Moon JJ; Li AV; Suh H; Irvine DJ
J Control Release; 2012 Feb; 157(3):354-65. PubMed ID: 21820024
[TBL] [Abstract][Full Text] [Related]
48. Angelica sinensis polysaccharide encapsulated into PLGA nanoparticles as a vaccine delivery and adjuvant system for ovalbumin to promote immune responses.
Gu P; Liu Z; Sun Y; Ou N; Hu Y; Liu J; Wu Y; Wang D
Int J Pharm; 2019 Jan; 554():72-80. PubMed ID: 30399435
[TBL] [Abstract][Full Text] [Related]
49. Dual dye in-vivo imaging of differentially charged PLGA carriers reveals antigen-depot effect, leading to improved immune responses in preclinical models.
Riehl M; Harms M; Lucas H; Ebensen T; Guzmán CA; Mäder K
Eur J Pharm Sci; 2018 May; 117():88-97. PubMed ID: 29408551
[TBL] [Abstract][Full Text] [Related]
50. Intracellular signaling pathway in dendritic cells and antigen transport pathway in vivo mediated by an OVA@DDAB/PLGA nano-vaccine.
Han S; Ma W; Jiang D; Sutherlin L; Zhang J; Lu Y; Huo N; Chen Z; Engle JW; Wang Y; Xu X; Kang L; Cai W; Wang L
J Nanobiotechnology; 2021 Nov; 19(1):394. PubMed ID: 34838057
[TBL] [Abstract][Full Text] [Related]
51. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen.
Saluja SS; Hanlon DJ; Sharp FA; Hong E; Khalil D; Robinson E; Tigelaar R; Fahmy TM; Edelson RL
Int J Nanomedicine; 2014; 9():5231-46. PubMed ID: 25419128
[TBL] [Abstract][Full Text] [Related]
52. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines.
Waeckerle-Men Y; Groettrup M
Adv Drug Deliv Rev; 2005 Jan; 57(3):475-82. PubMed ID: 15560953
[TBL] [Abstract][Full Text] [Related]
53. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.
Shen H; Ackerman AL; Cody V; Giodini A; Hinson ER; Cresswell P; Edelson RL; Saltzman WM; Hanlon DJ
Immunology; 2006 Jan; 117(1):78-88. PubMed ID: 16423043
[TBL] [Abstract][Full Text] [Related]
54. In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A.
Sarti F; Perera G; Hintzen F; Kotti K; Karageorgiou V; Kammona O; Kiparissides C; Bernkop-Schnürch A
Biomaterials; 2011 Jun; 32(16):4052-7. PubMed ID: 21377204
[TBL] [Abstract][Full Text] [Related]
55. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution.
Zhuang Y; Ma Y; Wang C; Hai L; Yan C; Zhang Y; Liu F; Cai L
J Control Release; 2012 Apr; 159(1):135-42. PubMed ID: 22226776
[TBL] [Abstract][Full Text] [Related]
56. Poly(d,l)-lactide-co-glycolide (PLGA) microspheres as immunoadjuvant for Brugia malayi antigens.
Saini V; Verma SK; Murthy PK; Kohli D
Vaccine; 2013 Aug; 31(38):4183-91. PubMed ID: 23827312
[TBL] [Abstract][Full Text] [Related]
57. Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles.
Kumar A; Wonganan P; Sandoval MA; Li X; Zhu S; Cui Z
J Control Release; 2012 Oct; 163(2):230-9. PubMed ID: 22921518
[TBL] [Abstract][Full Text] [Related]
58. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery.
Zhang Z; Tongchusak S; Mizukami Y; Kang YJ; Ioji T; Touma M; Reinhold B; Keskin DB; Reinherz EL; Sasada T
Biomaterials; 2011 May; 32(14):3666-78. PubMed ID: 21345488
[TBL] [Abstract][Full Text] [Related]
59. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells.
Elamanchili P; Diwan M; Cao M; Samuel J
Vaccine; 2004 Jun; 22(19):2406-12. PubMed ID: 15193402
[TBL] [Abstract][Full Text] [Related]
60. The effect of poly(D,L-lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens.
Yang YW; Hsu PY
Biomaterials; 2008 Jun; 29(16):2516-26. PubMed ID: 18329708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
